For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Antineoplastic drugs, also known as anticancer drugs, anti-malignant drugs, refer to drugs for the treatment of malignant tumors.
Scope of the Report:
This report focuses on the Anticancer Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Simply put, there are chemotherapy drugs and biological agents. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of tumors; the invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry, and genetic engineering have accelerated the process of drug development; research and development of anti-tumor drugs have been Enter a new era.
At present, there are more than 80 kinds of anti-cancer drugs commonly used in clinical practice in the world, which can be roughly divided into the following 6 categories: cytotoxic drugs, hormone drugs, biological response modifiers, monoclonal antibody drugs, other drugs, and auxiliary drugs.
The worldwide market for Anticancer Drugs is expected to grow at a CAGR of roughly 8.0% over the next five years, will reach 141900 million US$ in 2023, from 89300 million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- CELGENE CORPORATION
- Novartis AG
- Pfizer Inc
- Amgen Inc
- Bayer AG
- Takeda Pharmaceutical Company Limited
- Merck & Co.
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Cytotoxic Drugs (Alkylating Agents, and Antimetabolites)
- Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors)
- Hormonal Drugs
Market Segment by Applications, can be divided into
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
There are 15 Chapters to deeply display the global Anticancer Drugs market.
Chapter 1, to describe Anticancer Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Anticancer Drugs, with sales, revenue, and price of Anticancer Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Anticancer Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Anticancer Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Anticancer Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source